Increased IL-1β and caspase-1 levels have been observed in patients with early or mild stages of AD, which suggests that NLRP3 inflammasome activation may contribute to early pathogenic events that stimulate the progression of AD [19,67,71,72,73]. The gene discussed is NLRP3; the disease is Alzheimer disease.